Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Steve Shallcross, the Company's Chief Financial Officer, has been named interim CEO to succeed Jeff Riley, who has resigned as an officer and director of the Company, effective immediately, for personal reasons.
Jeffrey Kraws, the Company's non-executive Independent Chairman of the Board stated, "The Board is very confident in the ability of Steve Shallcross and Joe Sliman, the Company's Chief Medical Officer, to continue the Company's development activities. We understand Jeff's decision to step down as CEO and as a Board member and are grateful for his leadership and accomplishments. During his tenure, he has led significant changes at the Company, including its transition to a company focused on therapeutics that preserve the microbiome. On behalf of the Board and the Company, we thank Jeff for his dedication and many years of service, and wish him all the best in his future endeavors."
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.